Later, Xu et al. reported the results of another phase 1 clinical study (NCT02942329) which aimed to investigate the efficacy of SHR-1210 (anti-PD-1 antibody) plus apatinib (VEGFR2 TKI) in refractory hepatocellular cancer (HCC), gastric cancer (GC), and esophagogastric junction cancer (EGJC) patients [97]. Here, PDCD1 is linked to gastric cancer.